Literature DB >> 15756008

B7-h4 is highly expressed in ductal and lobular breast cancer.

Barbara Tringler1, Shaoqiu Zhuo, Glenn Pilkington, Kathleen C Torkko, Meenakshi Singh, M Scott Lucia, David E Heinz, Jackie Papkoff, Kenneth R Shroyer.   

Abstract

PURPOSE: This study was designed to investigate the expression of B7-H4 protein, a member of the B7 family that is involved in the regulation of antigen-specific immune responses, in normal breast and in primary and metastatic breast carcinomas. EXPERIMENTAL
DESIGN: Archival formalin-fixed tissue blocks from breast cancers and normal somatic tissues were evaluated for B7-H4 expression by immunohistochemistry with manual and automated image analysis. The proportion of B7-H4-positive cells and the intensity of B7-H4 staining were compared with histologic type, grade, stage, hormone receptor status, and HER-2/neu status.
RESULTS: B7-H4 was detected in 165 of 173 (95.4%) primary breast cancers and in 240 of 246 (97.6%) metastatic breast cancers. B7-H4 staining intensity was greater in invasive ductal carcinomas [24.61 relative units (RU)] and in invasive lobular carcinomas (15.23 RU) than in normal breast epithelium (4.30 RU, P = 0.0003). Increased staining intensity was associated with negative progesterone receptor status (P = 0.014) and history of neoadjuvant chemotherapy (P = 0.004), and the proportion of B7-H4-positive cells was associated with negative progesterone receptor (P = 0.001) and negative HER-2/neu (P = 0.024) status. However, there was no statistically significant relationship between the proportion of B7-H4-positive cells or staining intensity and grade, stage, or other clinicopathologic variables. Low levels of B7-H4 expression were also detected in epithelial cells of the female genital tract, lung, pancreas, and kidney, but B7-H4 was generally absent in most other normal somatic tissues.
CONCLUSIONS: The nearly ubiquitous expression of B7-H4 in breast cancer, independent of tumor grade or stage, suggests a critical role for this protein in breast cancer biology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756008     DOI: 10.1158/1078-0432.CCR-04-1658

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  87 in total

1.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

2.  Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile.

Authors:  Wenbo Ke; Li Zeng; Yunbi Hu; Sisi Chen; Min Tian; Qinggang Hu
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

3.  B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.

Authors:  Amy E Krambeck; R Houston Thompson; Haidong Dong; Christine M Lohse; Eugene S Park; Susan M Kuntz; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

Review 4.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

Review 5.  Inhibitory costimulation and anti-tumor immunity.

Authors:  Natalia Martin-Orozco; Chen Dong
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

6.  B7-H4-deficient mice display augmented neutrophil-mediated innate immunity.

Authors:  Gefeng Zhu; Mathew M Augustine; Takeshi Azuma; Liqun Luo; Sheng Yao; Sudarshan Anand; A Cecilia Rietz; Jiaqiang Huang; Haiying Xu; Andrew S Flies; Sarah J Flies; Koji Tamada; Marco Colonna; Jan M A van Deursen; Lieping Chen
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

7.  B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells.

Authors:  Hyoung Kyu Kim; In-Sung Song; Sun Young Lee; Seung Hun Jeong; Sung Ryul Lee; Hye Jin Heo; Vu Thi Thu; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Dae Hun Jeong; Young Nam Kim; Jin Han
Journal:  Pflugers Arch       Date:  2014-12       Impact factor: 3.657

Review 8.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

Review 9.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

10.  Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance.

Authors:  Yiting Geng; Hui Wang; Changqing Lu; Qing Li; Bin Xu; Jingting Jiang; Changping Wu
Journal:  Int J Clin Oncol       Date:  2014-05-09       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.